Alpha Tau Medical Ltd(DRTS)

Biotechnology · Jerusalem, JM

$14.57-0.32 (-2.15%)

Delayed quote: Oct 6, 2026, 10:10 AM EDT

PS Ratio: N/A

Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/S ratio is N/A as of 2026-10-06T14:11:40.498Z.

Stored calculation inputs

Calculation as of: 2026-10-06T14:11:40.498Z.

Quote observation: 2026-10-06T14:10:14.000Z. Amounts in USD. The price header may show a later quote.

Quote market capitalization: 1,316,048,013
TTM revenue · period ending 2026-06-30: 0

FMP input reference: d0cade57d6bc8828dc71ac364ddc44a4328d7c948fb2699a56d4eea8e3f6e5b7

P/E Ratio|Gross Margin|Revenue Growth|All Metrics

Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.

DRTS PS Ratio Metrics

PS RATIO

N/A

DRTS Competitors' PS Ratio

DRTS

Alpha Tau Medical Ltd

Current

Market Cap

$1.32B

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

AVBP

ArriVent BioPharma, Inc.

vs DRTS

Market Cap

$1.33B

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

COAG

Hemab Therapeutics Holdings, Inc. Common Stock

vs DRTS

Market Cap

$1.34B

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

KLRA

Kailera Therapeutics, Inc.

vs DRTS

Market Cap

$1.35B

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INBX

Inhibrx Biosciences Inc.

vs DRTS

Market Cap

$1.40B

PS Ratio

N/A

TTM Avg

865.07

3Y Avg

1036.91

5Y Avg

726.94

KARD

Kardigan, Inc.

vs DRTS

Market Cap

$1.22B

PS Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CRON

Cronos Group Inc.

vs DRTS

Market Cap

$1.22B

PS Ratio

5.42

TTM Avg

6.20

3Y Avg

7.49

5Y Avg

10.16

INNV

Innovage Holding Corp.

vs DRTS

Market Cap

$1.22B

PS Ratio

1.23

TTM Avg

1.18

3Y Avg

0.95

5Y Avg

1.06

MNKD

MannKind Corporation

vs DRTS

Market Cap

$1.21B

PS Ratio

3.07

TTM Avg

3.95

3Y Avg

5.37

5Y Avg

8.24

ANAB

AnaptysBio, Inc.

vs DRTS

Market Cap

$1.43B

PS Ratio

6.00

TTM Avg

6.28

3Y Avg

11.75

5Y Avg

20.01

NAME	MARKET CAP	PS RATIO	TTM	3Y	5Y
Alpha Tau Medical Ltd (DRTS)	$1.32B	N/A	N/A	N/A	N/A
ArriVent BioPharma, Inc. (AVBP)vs ›	$1.33B	N/A	N/A	N/A	N/A
Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs ›	$1.34B	N/A	N/A	N/A	N/A
Kailera Therapeutics, Inc. (KLRA)vs ›	$1.35B	N/A	N/A	N/A	N/A
Inhibrx Biosciences Inc. (INBX)vs ›	$1.40B	N/A	865.07	1036.91	726.94
Kardigan, Inc. (KARD)vs ›	$1.22B	N/A	N/A	N/A	N/A
Cronos Group Inc. (CRON)vs ›	$1.22B	5.42	6.20	7.49	10.16
Innovage Holding Corp. (INNV)vs ›	$1.22B	1.23	1.18	0.95	1.06
MannKind Corporation (MNKD)vs ›	$1.21B	3.07	3.95	5.37	8.24
AnaptysBio, Inc. (ANAB)vs ›	$1.43B	6.00	6.28	11.75	20.01

How this was calculated

Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.

Revenue calculation and filing references
Fiscal period	Revenue	Source
Q3 FY2025Period ended 2025-09-30	$0	Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-09-30
Q4 FY2025Period ended 2025-12-31	$0	Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-09
Q1 FY2026Period ended 2026-03-31	$0	Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-31
Q2 FY2026Period ended 2026-06-30	$0	Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-10
TTM revenue	$0

The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.

These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.

Sales Valuation

P/S Ratio

N/A

Market Cap / Trailing Twelve-Month Revenue

PS Ratio Formula & Definition

PS Ratio = Market Cap / Revenue (TTM)

The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

PS Ratio: N/A

DRTS PS Ratio Metrics

DRTS Competitors' PS Ratio

Sales Valuation

PS Ratio Formula & Definition

Related Metrics